NANOGENICS Trademark

Trademark Overview


On Thursday, August 9, 2018, a trademark application was filed for NANOGENICS with the United States Patent and Trademark Office. The USPTO has given the NANOGENICS trademark a serial number of 88072409. The federal status of this trademark filing is REGISTERED as of Tuesday, July 14, 2020. This trademark is owned by Nanogenics Limited. The NANOGENICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bon...

Medical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological research, clinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals an...
nanogenics

General Information


Serial Number88072409
Word MarkNANOGENICS
Filing DateThursday, August 9, 2018
Status700 - REGISTERED
Status DateTuesday, July 14, 2020
Registration Number6098589
Registration DateTuesday, July 14, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 25, 2020

Trademark Statements


Goods and ServicesPharmaceutical and natural remedies for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, cystic fibrosis, glaucoma, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing siRNA, RNA, shRNA, mRNA or DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver diseases, immune system-related diseases and disorders, and diseases of the brain; pharmaceutical medical preparations being nanoparticles for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing siRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing shRNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing mRNA for treatments in the form of gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing DNA for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations being pharmaceuticals containing lipids, liposomes or peptides for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; medical preparations for use in gene therapy for the treatment of tumours; biochemical preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; biological preparations for medical purposes for use in relation to gene therapy for the treatment of cancer, respiratory diseases and disorders, eye diseases, bone diseases, vascular diseases, liver disease, immune system-related diseases and disorders, and diseases of the brain; reagents for medical use; reagents for use in medical genetic testing; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations being nanoparticles for the treatment of cancer; pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA for the treatment of cancer; pharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; chemotherapeutics for use in the treatment of cancer; pharmaceutical preparations for use in chemotherapy for the treatment of cancer; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations for the treatment and prevention of tumours; drug delivery agents in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals ; drug delivery agents being made from lipids, liposomes or peptides in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations in the form of nanoparticles; drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material in the form of nanoparticles; drug delivery agents for use in gene therapy in the form of nanoparticles that facilitate the delivery of a wide variety of pharmaceuticals; drug delivery agents being nanoparticles in the form of an artificial virus that facilitate the delivery of a wide variety of pharmaceuticals; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; none of the aforesaid for use in relation to the treatment of hair loss or hair growth stimulation
Goods and ServicesMedical and pharmacological research services all in the field of gene therapy and treatment of cancer; biological research, clinical research and medical research all in the field of gene therapy; research in the field of gene therapy; scientific research for medical purposes in the area of cancerous diseases; pharmaceutical product development; research of pharmaceuticals; research relating to pharmaceutical delivery agents; development of pharmaceutical delivery agents; research and development in the pharmaceutical and biotechnology fields; providing information about the results of clinical trials for pharmaceutical products; scientific research services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; development of pharmaceutical preparations and substances; development of pharmaceuticals and pharmaceutical preparations being nanoparticles; development of pharmaceuticals and pharmaceutical preparations containing siRNA, RNA, shRNA, mRNA or DNA; development of drug delivery agents being made from lipids, liposomes or peptides; development of drug delivery agents that facilitate the delivery of pharmaceuticals and pharmaceutical preparations; development of pharmaceutical and drug delivery agents for use in relation to the delivery of siRNA, shRNA, mRNA, RNA, DNA or other genetic material; development of pharmaceuticals and pharmaceutical preparations for use in gene therapy; development of drug delivery agents for use in gene therapy; development of drug delivery agents being nanoparticles; providing consulting to medical research companies in the design and conduct of clinical trials and proving consulting to pharmaceutical companies in the design of pharmaceutical products

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 17, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 17, 2018
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNanogenics Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressLondon N120DR
GB

Party NameNanogenics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressLondon N120DR
GB

Party NameNanogenics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressLondon N120DR
GB

Trademark Events


Event DateEvent Description
Tuesday, July 14, 2020REGISTERED-PRINCIPAL REGISTER
Wednesday, June 10, 20201(B) BASIS DELETED; PROCEED TO REGISTRATION
Wednesday, April 29, 2020NOTICE OF ALLOWANCE CANCELLED
Monday, June 8, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 29, 2020TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, April 28, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, April 28, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 28, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 21, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 25, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 25, 2020PUBLISHED FOR OPPOSITION
Wednesday, February 5, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 21, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, December 28, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, December 27, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 27, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, June 30, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, June 30, 2019NON-FINAL ACTION E-MAILED
Sunday, June 30, 2019NON-FINAL ACTION WRITTEN
Monday, June 3, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 3, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 30, 2019ASSIGNED TO LIE
Monday, May 27, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, November 25, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, November 25, 2018NON-FINAL ACTION E-MAILED
Sunday, November 25, 2018NON-FINAL ACTION WRITTEN
Thursday, November 15, 2018ASSIGNED TO EXAMINER
Friday, August 17, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, August 13, 2018NEW APPLICATION ENTERED IN TRAM